Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)

A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.

Also Known As:

Networked: 1214 relevant articles (95 outcomes, 192 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Lymphoma (Lymphomas)
2.	T-Cell Lymphoma (Lymphoma, T Cell)
3.	Neoplasms (Cancer)
4.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
5.	Non-Hodgkin Lymphoma (Lymphosarcoma)

Experts

1.	Pro, Barbara: 25 articles (10/2022 - 09/2002)
2.	Gaulard, Philippe: 22 articles (01/2022 - 03/2002)
3.	Zinzani, Pier Luigi: 21 articles (10/2022 - 05/2005)
4.	Tobinai, Kensei: 19 articles (10/2022 - 03/2010)
5.	Kim, Won Seog: 19 articles (03/2022 - 03/2007)
6.	Horwitz, Steven M: 17 articles (10/2022 - 01/2008)
7.	O'Connor, Owen A: 17 articles (10/2022 - 07/2010)
8.	Savage, Kerry J: 17 articles (10/2022 - 01/2008)
9.	Horwitz, Steven: 14 articles (10/2020 - 07/2006)
10.	Foss, Francine: 14 articles (10/2019 - 06/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Peripheral T-Cell Lymphoma:

1.	romidepsin (FK228)FDA Link 02/20/2012 - "The primary objective of this international, pivotal, single-arm, phase II trial was to confirm the efficacy of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). " 01/01/2022 - "Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)." 11/01/2017 - "Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study." 10/01/2017 - "Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials." 01/01/2017 - "Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial."
2.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/01/2023 - "Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source." 01/01/2023 - "The use of post-transplantation cyclophosphamide (PTCy) for graft-versus host-disease (GVHD) prophylaxis has revolutionized allogeneic blood or marrow transplantation (alloBMT), but there is limited published experience in peripheral T cell lymphoma (PTCL). " 01/01/2011 - "Continuous oral cyclophosphamide and prednisolone as a valuable treatment option for peripheral T cell lymphoma." 06/01/2006 - "We report a case of refractory peripheral T-cell lymphoma (PTCL) successfully treated with a combination of fludarabine and cyclophosphamide (FLU/CY). " 06/01/2006 - "Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide."
3.	Vincristine (Oncovin)FDA LinkGeneric 03/01/2015 - "We performed a phase II study of biweekly THP-COP [50 mg/m(2) pirarubicin, 750 mg/m(2) cyclophosphamide, 1.4 mg/m(2) vincristine (2.0 mg maximum) on day 1, and 100 mg/body predonisolone on days 1-5] in patients with peripheral T-cell lymphoma (PTCL). " 01/01/2022 - "Patients aged <65 years with peripheral T-cell lymphoma (PTCL) are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). " 12/01/2017 - "While cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is the most commonly used chemotherapeutic regimen for patients with peripheral T-cell lymphomas (PTCLs), elderly patients are more vulnerable to associated toxicities. " 10/01/2014 - "Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens such as cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and results in a 5-year overall survival (OS) rate of less than 50%. " 04/01/2014 - "The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma."
4.	Prednisone (Sone)FDA LinkGeneric 10/13/2023 - "Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial." 01/01/2022 - "Patients aged <65 years with peripheral T-cell lymphoma (PTCL) are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). " 01/01/2020 - "Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients." 01/01/2019 - "Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China." 10/01/2014 - "Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens such as cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and results in a 5-year overall survival (OS) rate of less than 50%. "
5.	Doxorubicin (Adriamycin)FDA LinkGeneric 09/01/2002 - "There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. " 09/01/2002 - "Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas." 09/01/2002 - "From 1985 to 1998, 39 patients with Stage I or II World Health Organization classification anaplastic large cell lymphoma (ALCL; n = 20), peripheral T-cell lymphoma, unspecified (PTCLu; n = 11), or nasal-type NK/T-cell lymphoma (NKTCL; n = 8) were treated using doxorubicin-based chemotherapy (median, 6 cycles) with (n = 24) or without (n = 15) radiotherapy (median dose, 40 Gy). " 06/01/2017 - "CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin." 01/01/2017 - "Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma."
6.	10-propargyl-10-deazaaminopterinFDA Link 10/01/2017 - "These results indicate that pralatrexate is generally well tolerated and effective in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. " 08/01/2012 - "Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma." 01/01/2012 - "Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma." 11/26/2020 - "Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial." 10/01/2017 - "Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma."
7.	Brentuximab VedotinIBA 01/01/2019 - "FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma." 01/01/2022 - "Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study." 10/01/2014 - "Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study." 01/01/2021 - "Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin." 12/26/2019 - "The development of brentuximab vedotin has opened a new era in the management of peripheral T-cell lymphomas (PTCLs). "
8.	Alemtuzumab (Campath)FDA Link 02/01/2009 - "Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study." 01/01/2021 - "Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial." 11/01/2013 - "CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial." 08/15/2008 - "As part of an ongoing phase 2 trial in which we recently treated 20 patients with 8 cycles of CHOP every 2 weeks with 3 additional doses of 30 mg alemtuzumab per cycle, we observed the development of Epstein-Barr virus (EBV)-positive lymphoproliferative disease, after completion of the immunochemotherapy in 3 patients with peripheral T-cell lymphoma. " 05/01/2005 - "We assessed the impact of a reduced-dose (10 mg x 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. "
9.	mogamulizumabIBA 10/01/2017 - "Progression-free survival (PFS) and overall survival (OS) of ATL patients enrolled in two studies are herein updated, namely NCT00355472 (phase I study of mogamulizumab in relapsed patients with ATL and peripheral T-cell lymphoma) and NCT00920790 (phase II study for relapsed ATL). " 11/01/2011 - "A phase I study of KW-0761 in relapsed ATL and peripheral T-cell lymphoma was started in 2006, and a subsequent phase II study was completed in 2010. " 10/01/2015 - "Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab." 07/01/2015 - "Erratum to: Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab." 02/01/2016 - "Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report."
10.	belinostatIBA 03/01/2017 - "Belinostat is a safe and effective treatment option for relapsed and refractory peripheral T-cell lymphoma, with many future applications currently being investigated." 08/10/2015 - "Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study." 12/01/2011 - "The data from these studies were analysed to summarise the progress of belinostat from Phase I to a current pivotal trial in peripheral T-cell lymphoma. " 01/01/2018 - "Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas." 01/01/2018 - "Belinostat received regulatory approval in the USA on July 3, 2014, for use against peripheral T-cell lymphoma. "

Therapies and Procedures

1.	Therapeutics 01/01/2019 - "High-dose therapy and autologous HCT is recommended in first complete remission for most systemic (non-cutaneous) nodal subtypes, or peripheral T-cell lymphomas (PTCL). " 11/01/2017 - "Patients with relapsed or refractory peripheral T-cell lymphoma display a dismal prognosis and their therapy represents an unmet medical need, as the best treatment strategy is yet to be determined. " 11/07/2020 - "Novel epigenetic-targeted drugs have shown good tolerance and therapeutic effects in the treatment of peripheral T-cell lymphoma as monotherapy or combination therapy. " 12/01/2003 - "The aim of this study was to analyze the efficacy of this therapy in the corresponding patients with peripheral T-cell lymphoma (PTCL). " 01/01/2022 - "A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma."
2.	Stem Cell Transplantation 01/01/2019 - "The role of autologous stem cell transplantation (ASCT) in the first complete remission (CR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. " 01/01/2019 - "The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study." 01/01/2016 - "Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas." 12/01/2020 - "Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34+ cells is associated with improved survival." 12/01/2023 - "Efficacy of ex vivo purging with CD34+ selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients."
3.	Drug Therapy (Chemotherapy) 11/04/2019 - "However, she was diagnosed as peripheral T cell lymphoma, not otherwise specified (PTCL-NOS) by the pulmonary nodular and the skin biopsy almost 10 years later, and she got complete remission within 1 year after chemotherapy. " 08/01/2016 - "Of these patients, 77 % were International Prognostic Index (IPI) >1 and 79 % had a prognostic index for peripheral T-cell lymphoma (PIT) >1. Of 75 patients who received systemic chemotherapy, the complete remission rate was 60 %, the relapse rate was 47 %, and the 2-year progression-free survival rate was 37.4 %. " 08/01/2009 - "Since prognosis of patients with peripheral T-cell lymphoma, not otherwise specified are very poor with conventional chemotherapy, auto-HCT during first remission is being explored in peripheral T-cell lymphoma. " 01/01/2009 - "A final diagnosis of peripheral T cell lymphoma, not otherwise specified (WHO) was made, and complete remission was achieved by chemotherapy. " 11/01/2015 - "This lesion was therefore diagnosed as "CM+, EBV-associated high-grade peripheral T-cell lymphoma." After 5 cycles of chemotherapy, the patient was in remission 8 months following initial diagnosis. "
4.	Combination Drug Therapy (Combination Chemotherapy) 01/01/2022 - "Optimal treatment strategies for (relapsed and refractory [R/R]) peripheral T-cell lymphoma (PTCL) have not been well defined, and with the approval of several novel single agents (SA), the comparative efficacy of combination chemotherapy (CC) to single-agent strategies remains unclear. " 02/01/2015 - "A total of 102 newly diagnosed patients with peripheral T-cell lymphoma who received combination chemotherapy with or without L-ASP were enrolled in the study between January 2011 and December 2013 in our hospital. " 01/01/2019 - "Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry." 02/01/2015 - "Combination chemotherapy with L-ASP showed better short-term efficacy in newly diagnosed peripheral T-cell lymphoma patients and the adverse effects were controllable. " 01/01/2013 - "[Successful therapy for enteropathy-associated peripheral T-cell lymphoma using high-dose polychemotherapy and autologous hematopoietic stem cell transplantation]."
5.	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 05/01/2019 - "There was limited information about the efficacy of myeloablative allogeneic peripheral blood stem cell transplantation (allo-PBSCT) in non-complete remission (non-CR) patients with relapsed/refractory peripheral T cell lymphomas (PTCLs). " 05/01/2019 - "Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas." 07/01/2016 - "In this study, to investigate clinical characteristics, response, outcome, and prognosis of peripheral blood stem cell transplantation (PBSCT) for patients with peripheral T-cell lymphoma (PTCL). " 09/14/2018 - "Objective: To evaluate clinical outcomes of autologous and allogeneic peripheral blood stem cell transplantation (PBSCT) for aggressive peripheral T-cell lymphoma (PTCL). " 09/14/2018 - "[Clinical outcomes of peripheral blood stem cell transplantation for aggressive peripheral T-cell lymphoma]."